Efficacy of treatment with intravenous immunoglobulins and pulse therapies with methylprednisolone and cyclophosphamide in patients with active SLE

Immunoglobulin preparations for intravenous administration (IVIG) contain highly purified native molecules of human IgG, freed from high-molecular aggregates and vasoactive substances stabilized with glucose, maltose, glycine, sorbitol, etc. Intravenous immunoglobulins can be used as adjunctive therapy in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APLS) with recurrent miscarriages. The aim of the clinical observation is to establish the efficacy of the treatment of immunovenin in a scheme, in parallel with pulse therapies with methylprednisolone (MP) and cyclophosphamide (CYC) in patients with active SLE, compared with the application of pulse therapies with methylprednisolone and cyclophosphamide alone. When comparing the effect of treatment with immunovenin 400 mg/kg body weight every 3 months for a period of 12 to 18 months, in parallel with pulse therapies with methylprednisolone and cyclophosphamide 1 g monthly intravenously in disease activity, a significant difference in positive influence on organic brain syndrome, cranial nerve function, arthritis/arthralgias and proteinuria. In both groups, the concentration of anti dsDNA and ACLA decreased to the same extent. Treatment with immunovenin has a positive effect on influencing disease activity in SLE, added to treatment with pulse therapies with methylprednisolone and cyclophosphamide.